Table 2.
Characteristics of the study population in the RNAseq study and the validation analyses.
| N | Sex (% Female) | Age (Mean ± SD) | FeNO, ppb (Mean ± SD) | IgE, kU/l (Median ± IQR) | |
|---|---|---|---|---|---|
| RNAseq study | |||||
| Controls | 30 | 46.7 | 57 ± 17 | - | 46.7 ± 87.8 |
| Asthmatic patients | 30 | 56.7 | 30 ± 13 | - | 179.0 ± 239.0 |
| Validation analysis | |||||
| Controls | 100 | 66.0 | 57 ± 17 | - | 28.8 ± 57.7 |
| Asthmatic patients | 187 | 55.1 | 45 ± 19 | 44.8 ± 48.3 | 174.0 ± 398.2 |
| Non-allergic asthma (NAA) | 76 | 60.5 | 58 ± 15 | 38.1 ± 40.6 | 77.0 ± 118.8 |
| NAA without NP | 33 | 72.7 | 56 ± 16 | 24.8 ± 19.3 | 37.9 ± 103.5 |
| NAA with NP | 43 | 51.2 | 61 ± 14 | 52.2 ± 51.7 | 83.0 ± 258.7 |
| Allergic asthma (AA) | 111 | 51.4 | 35 ± 16 | 49.8 ± 53.0 | 312.5 ± 472.3 |
| AA without NP | 82 | 57.3 | 31 ± 14 | 39.8 ± 29.5 | 312.5 ± 445.5 |
| AA with NP | 29 | 34.5 | 46 ± 17 | 79.6 ± 88.7 | 307.0 ± 747.0 |
| Early-onset asthma | 76 | 61.8 | 31 ± 17 | 42.5 ± 43.1 | 271.0 ± 402.1 |
| Late-onset asthma | 111 | 50.5 | 54 ± 16 | 46.5 ± 51.9 | 126.0 ± 406.5 |
| Non-eosinophilic asthma | 32a | 59.4 | 44 ± 17 | 26.4 ± 18.2 | 109.0 ± 260.5 |
| Eosinophilic asthma | 120a | 53.3 | 46 ± 20 | 49.7 ± 54.5 | 196.0 ± 405.4 |
SD, standard deviation; IQR, interquartile range.
a
Blood eosinophil counts were not available for all non-eosinophilic and eosinophilic asthma patients.